^
Association details:
| Biomarker: | AR overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
Excerpt:
In the PREPARE trial, a dose-dense treatment arm was compared with a standard treatment arm. Regarding overall survival, patients with high AR1 mRNA levels receiving the standard treatment had better survival compared to patients with low AR1 mRNA levels (HR 0.41 (95% CI 0.22–0.74)...
Secondary therapy:
EC
DOI:
10.1038/s41416-019-0630-3
Trial ID:
Test:
